Oncology NPs, PAs, and nurses
After completing this activity, participants should be better able to:
Develop guideline-directed, individualized treatment approaches for use of CDK4/6 inhibitors in HR-positive/HER2-negative early and advanced breast cancer
Implement recommended strategies for identifying and managing toxicities associated with CDK4/6 inhibitors
Integrate patient education and feedback to optimize patient experiences during treatment and survivorship
All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Jeremy Force, DO: consultant/speaker: Nanostring, Pfizer; researcher: Exact Sciences, G1 Therapeutics, Xilis.
Christie Hilton, DO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.
Kathleen Madden, MSN: consultant/advisor/speaker: Novartis.
The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Christie Hilton, DO, as noted above.
Learners wishing to earn CE/CME credit must:
The estimated time to complete this activity is 1.00 hour.
Release date: December 30, 2022
Expiration date: December 29, 2023
This program has been made available online.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 29, 2023. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.